Alkermes plc (ALKS)
NASDAQ: ALKS · Real-Time Price · USD
42.45
-0.35 (-0.82%)
At close: Jun 8, 2026, 4:00 PM EDT
42.00
-0.45 (-1.06%)
After-hours: Jun 8, 2026, 7:08 PM EDT
Alkermes Revenue
Alkermes had revenue of $392.91M in the quarter ending March 31, 2026, with 28.19% growth. This brings the company's revenue in the last twelve months to $1.56B, up 3.21% year-over-year. In the year 2025, Alkermes had annual revenue of $1.48B, down -5.25%.
Revenue (ttm)
$1.56B
Revenue Growth
+3.21%
P/S Ratio
4.53
Revenue / Employee
$762,098
Employees
2,050
Market Cap
7.08B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.48B | -81.73M | -5.25% |
| Dec 31, 2024 | 1.56B | -105.78M | -6.36% |
| Dec 31, 2023 | 1.66B | 551.61M | 49.61% |
| Dec 31, 2022 | 1.11B | -61.95M | -5.28% |
| Dec 31, 2021 | 1.17B | 134.99M | 13.00% |
| Dec 31, 2020 | 1.04B | -132.19M | -11.29% |
| Dec 31, 2019 | 1.17B | 76.68M | 7.01% |
| Dec 31, 2018 | 1.09B | 190.90M | 21.13% |
| Dec 31, 2017 | 903.37M | 157.68M | 21.15% |
| Dec 31, 2016 | 745.69M | 117.36M | 18.68% |
| Dec 31, 2015 | 628.34M | 9.55M | 1.54% |
| Dec 31, 2014 | 618.79M | 464.31M | 300.57% |
| Dec 31, 2013 | 154.48M | -421.07M | -73.16% |
| Mar 31, 2013 | 575.55M | 185.57M | 47.59% |
| Mar 31, 2012 | 389.98M | 203.34M | 108.95% |
| Mar 31, 2011 | 186.64M | 8.36M | 4.69% |
| Mar 31, 2010 | 178.28M | -148.56M | -45.45% |
| Mar 31, 2009 | 326.84M | 86.12M | 35.78% |
| Mar 31, 2008 | 240.72M | 752.00K | 0.31% |
| Mar 31, 2007 | 239.97M | 73.36M | 44.04% |
| Mar 31, 2006 | 166.60M | 90.48M | 118.85% |
| Mar 31, 2005 | 76.13M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Viatris | 14.56B |
| Elanco Animal Health | 4.89B |
| Dr. Reddy's Laboratories | 3.58B |
| Neurocrine Biosciences | 3.10B |
| Amneal Pharmaceuticals | 3.05B |
| Hims & Hers Health | 2.37B |
| Lantheus Holdings | 1.55B |
| Supernus Pharmaceuticals | 776.83M |
ALKS News
- 4 days ago - Alkermes to present new data on Alixorexton, LUMRYZ - TheFly
- 4 days ago - Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research - Business Wire
- 5 days ago - Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - Business Wire
- 13 days ago - Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting - Business Wire
- 18 days ago - Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences - Business Wire
- 26 days ago - Alkermes price target raised to $48 from $45 at Baird - TheFly
- 26 days ago - Alkermes Proxy statement: Proxy filing - Filings
- 27 days ago - Alkermes announces ‘positive’ topline results from REVITALYZ Phase 3 study - TheFly